Andrew Salzman

Dr. Salzman is a physician, scientist, inventor, and biomedical entrepreneur with more than 20 years of experience in biomedical drug discovery and development. He studied psychology and English literature at Yale College and medicine at Harvard Medical School. After a pediatric internship and residency at Columbia University (New York, NY), he undertook post-doctoral fellowships in pediatric critical care, neonatal critical care, immunology, epithelial biology, and pediatric infectious disease at the Weizmann Institute of Science in (Rehovot, Israel), Children’s Hospital Medical Center (Boston, MA), the Massachusetts General Hospital (Boston, MA), the University of Massachusetts Medical Center (Worcester, MA), and Beth Israel Hospital Medical Center (Brookline, MA).

Prior to his entrepreneurial career in biotechnology, he founded and led the Division of Critical Care Medicine at Children’s Hospital Medical Center (Cincinnati, OH), one of the largest pediatric critical care programs in North America. In 1999, Dr. Salzman left academia to found Inotek Pharmaceuticals, followed by the founding and leadership of a number of biotechnology companies in Israel and the United States: Radikal Therapeutics, Salzman Capital Ventures, Salzman Lovelace Investments, Menemsha Pharmaceuticals, Tisbury Pharmaceuticals, and Respirometics.

Over the past twenty years, Dr. Salzman has received funding for 135 NIH, DARPA, and BARDA grants totaling $160 million. This work has supported research activities resulting in 200 scientific publications and 5o patents, spanning work in ischemia-reperfusion injury, intestinal mucosal biology, pulmonary arterial hypertension, autoimmune disease, and mechanisms of pro-inflammatory gene expression.